AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Dare Bioscience, Inc. Director's Dealing 2014

Oct 31, 2014

34825_dirs_2014-10-31_0ee49b8c-2ad6-41f7-ab8a-54d9ce4ca88f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cerulean Pharma Inc. (CERU)
CIK: 0001401914
Period of Report: 2014-10-29

Reporting Person: GUIFFRE CHRISTOPHERD T (Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-10-29	Stock Option (Right to Buy)	$4.36	A	50300	Acquired	2024-10-28	Common Stock (50300)	Direct

Footnotes

F1: This option was granted on October 29, 2014. The option vests as to 2.08333% of the underlying shares monthly through and including October 29, 2018.